AAV with CMV-IVS promoter driven CreERT2

This AAV expresses CreERT2 driven by an ubiquitous CMV-IVS promoter.

The CMV-IVS promoter is about 1.1 kb in length and consists of the commonly used CMV promoter/enhancer and the intron (IVS) from beta-globin . The presence of intron elements was shown to give a higher level of transgene expression than that of the original CMV promoter/enhancer.

A mutated form of estrogen ligand-binding domain (ERT2) that binds to synthetic antagonists (such as tamoxifen or its derivative 4-hydroxy-tamoxifen) but not to circulating estrogen, was fused to the Cre recombinase (Cre) to create CreERT2 (also known as "inducible Cre"). When tamoxifen binds to CreERT2, it induces a conformational change of CreERT2, leading to its nuclear translocation, followed by Cre/Lox-mediated recombination.